MedTech Dive December 18, 2023
Rising interest rates, fears about the impact of GLP-1 drugs and “choppy supply-chain dynamics” dragged on the industry this year, the analysts wrote.
Dive Brief:
- A stable-to-improving environment characterized by falling inflation, low unemployment and the easing of hospital staffing pressures position medtech companies for a better year in 2024, BTIG analysts wrote in a note to investors.
- This year, “choppy supply-chain dynamics,” rising interest rates and fears about the impact of GLP-1 drugs dragged on the industry, causing stocks to underperform the S&P 500 despite companies benefiting from the conversion of procedure backlogs that built up during the pandemic.
- The BTIG analysts expect some of the factors that held medtech back this year to ease in 2024,...
Today's Sponsors
Today's Sponsor